Form 4: Baxter CEO Andrew Hider Receives Significant Equity Grants

Baxter International's President and CEO, Andrew Hider, was granted substantial equity awards, including restricted stock units and stock options, effective September 2, 2025.

Summary

• Andrew P. Hider, President and CEO of Baxter International Inc., received significant equity awards on September 2, 2025.
• These awards include 236,237 restricted stock units (RSUs) as a 'Make Whole Award' for unvested equity from his prior employer.
• An additional 131,813 RSUs were granted as part of Baxter's 2025 annual equity incentive compensation program.
• Hider also received 465,651 stock options with an exercise price of $24.17, also part of the 2025 annual equity incentive program.
• All RSU and stock option grants are scheduled to vest or become exercisable in three equal annual installments, commencing on September 2, 2026.
• The 'Make Whole Award' RSUs include a provision for immediate vesting upon certain employment termination events, specifically if employment is terminated by Baxter other than for Cause or by Hider for Good Reason, as defined in his Offer Letter effective July 7, 2025.

Sentiment

Score: 7

Explanation: The filing reports standard executive compensation, which is generally positive for aligning management interests with shareholders, but does not contain new operational or financial performance data to significantly alter sentiment.

Positives

• Significant equity grants to President and CEO Andrew P. Hider align his long-term financial interests with those of Baxter's shareholders.
• The 'Make Whole Award' demonstrates Baxter's commitment to attracting and retaining top executive talent by compensating for equity forfeited from a prior employer.
• The grants are part of the company's established 2025 annual equity incentive compensation program, indicating a structured approach to executive remuneration.

Future Outlook

The equity grants are structured with a three-year vesting schedule, aligning the CEO's incentives with the company's long-term performance and future strategic objectives. The 'Make Whole Award' also suggests a forward-looking strategy to secure and retain executive talent.

Industry Context

Executive equity compensation, including 'Make Whole Awards' for new hires and annual incentive grants, is a standard practice across the healthcare and medical technology industries. This approach is widely used to attract, retain, and motivate senior leadership by linking their compensation directly to company performance and shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options for executive compensation is a standard practice in the healthcare and medical technology sectors, comparable to peers like Medtronic (MDT) or Abbott Laboratories (ABT).
• 'Make Whole Awards' are frequently observed when companies recruit high-level executives, ensuring competitive compensation packages by replacing unvested equity from previous employers, a common practice in competitive talent markets.
• The three-year vesting schedule for these equity awards is typical for long-term incentive plans, aligning with industry benchmarks for executive retention and performance incentives.

Management Changes

Corporate Governance

Related Party Transactions

• Equity grants to Andrew P. Hider, President and CEO, as part of his compensation package, representing a transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: The grants align the CEO's long-term interests with shareholder value, potentially leading to improved performance, but also involve potential future dilution from share issuance upon vesting/exercise.
• Employees: Standard executive compensation practices can set a benchmark for other employee incentive programs within the company.
• Management: The grants serve as a key component of executive compensation, aiding in the retention and motivation of critical leadership talent.

Next Steps

• The granted RSUs and stock options will begin vesting/becoming exercisable in three equal annual installments starting September 2, 2026.
• Andrew P. Hider will continue in his roles as Director, President, and CEO of Baxter International Inc.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to Baxter's President and CEO, Andrew P. Hider. While these grants align management's interests with long-term shareholder value, they do not provide new operational or financial performance data that would fundamentally alter the investment thesis for Baxter International. Therefore, a 'hold' recommendation is appropriate as the filing confirms standard corporate governance and compensation practices without introducing new catalysts for significant price movement.

Keywords

Baxter International, BAX, Andrew Hider, SEC Form 4, Restricted Stock Units, Stock Options, Equity Compensation, CEO Compensation, Insider Transaction, Executive Compensation